Reed Jarvis
Optometrist · Murray, KYNPI 1578762449
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,307 of the $15,932 with a category attached, or 77.2%. 19 manufacturers reported payments, led by Lumenis BE Inc at 50.2% of the total. Reporting peaked in 2024 at $9,326 and has fallen 94.7% since, to $497 in 2025. Among optometrist clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $87.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$8K
- Alcon$5K
- Sun Pharmaceutical Industries Inc.$698
- Bausch & Lomb Americas Inc.$455
- Oyster Point Pharma, Inc.$345
- Tarsus Pharmaceuticals, Inc.$269
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$3,62523%
- Food & beverage$12,30777%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 1 | $7,993 |
| Alcon | 55 | $4,927 |
| Sun Pharmaceutical Industries Inc. | 31 | $698 |
| Bausch & Lomb Americas Inc. | 21 | $455 |
| Oyster Point Pharma, Inc. | 12 | $345 |
| Tarsus Pharmaceuticals, Inc. | 7 | $269 |
| AbbVie(2 entities) | 15 | $262 |
| Novartis | 13 | $244 |
| Coopervision Inc. | 5 | $225 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $181 |
| Kala Pharmaceuticals, Inc. | 4 | $69 |
| Lombart Brothers, Inc. | 1 | $50 |
| Johnson & Johnson Vision Care, Inc. | 1 | $49 |
| Astellas Pharma US Inc | 2 | $48 |
| Shire North American Group Inc | 3 | $43 |
| Dompe US, Inc. | 1 | $29 |
| Amgen | 1 | $17 |
| Harrow Eye, LLC | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- M22$7,993
- Precision 1$3,752
- DAILIES TOTAL1$3,625
- AIR OPTIX$2,000
- Air Optix plus HydraGlyde$1,500
- Dailies Aqua Comfort Plus$1,500
- Air Optix Color$1,000
- TOTAL30$660
- DAILIES TOTAL1 Multifocal$375
- XDEMVY$124
- TYRVAYA$122
- MiSight Contact Lens$117
- CEQUA$114
How this compares
$15,932 in reported general payments places this provider in the 95th percentile of 712 optometrist providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $459,878 |
| RestasisCyclosporine | 42 | $59,617 |
| MieboPerfluorohexyloctane/Pf | 23 | $18,554 |
| Cyclosporine | 17 | $17,650 |
| XiidraLifitegrast | 13 | $17,326 |
| VyzultaLatanoprostene Bunod | 25 | $11,892 |
| TyrvayaVarenicline Tartrate | 14 | $8,876 |
| Loteprednol Etabonate | 30 | $3,843 |
| Fluorometholone | 45 | $2,407 |
| Brimonidine Tartrate | 15 | $2,127 |
| Latanoprost | 88 | $837 |
| Prednisolone Acetate | 30 | $737 |
| Timolol Maleate | 35 | $625 |
| ErythromycinErythromycin Base | 12 | $109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $29 | $459,87812 claims |
| AbbVieRestasis | $262 | $59,61742 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $455 | $47,77261 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $345 | $8,87614 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $181 | $3,84330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 optometrist providers in Kentucky.
Other optometrist in Murray
- James JacoMurray$10K
- Paul KarpeckiLexington$3.6M
- Bilal AhmadLexington$150K
- Clay MattsonNicholasville$93K
- Ben LeonardCalvert City$75K
- Lee PeplinskiLouisville$74K
- Austin LifferthLouisville$72K
- Christopher KucLexington$52K
- Kristine Kerestan GarbigWilder$51K
- Renee ReederPikeville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.